Please email us at [email protected] with our item No, NDC#, UPC# or the product link if you have any quetions. We are located in Oceanside, California. Search over 110,000 items by Name, Item No., NDC, UPC (without dashes) or by Mfg.Name. Please note, Prescription items can only be ordered by a Drug Manufacturer, Wholesaler, Hospital, Governmental Medical Facility, VA, Pharmacy, Physician, Physician Assistant, Nurse Practitioner, Dentist, Podiatrist, Optometrist, Veterinarian, Naturopath, Licensed Lab, Physical Therapist & Pharmacist in their scope of practice. No order will ship, unless you you have provided us the Medical License (and DEA Lic. in case of controlled drug) and we had verified that. Rx items can only be shipped to AZ, AR, CA, CT, DE, FL, GA, GU, HI, IL, KS, KY, LA, ME, MA, MI, NJ, NY, PA, PR, TX, TN, VA, WA, WI and WV. If you are an International Physician or Pharmacist, please contact us before ordering.


Menu

Rx Item-Piqray 250mg Tab 28 By Novartis

PIQRAY 250MG TAB 28 By Novartis NDC Code(s): 0078-0701-51, 0078-0701-84, 0078-0708-02, 0078-0708-51, view more
Packager: Novartis Pharmaceuticals Corporation
Category: HUMAN PRESCRIPTION DRUG LABEL
PIQRAY 300MG TAB 56 By Novartis  Generic Name:
ALPELISIB

Description:
PIQRAY, 300MG, TABLETS, 2X28 EA

NDC:
00078-0708-02
UPC:
300780-708029PIQRAY 300MG TAB 56 By Novartis  Generic Name:
ALPELISIB

Description:
PIQRAY, 300MG, TABLETS, 2X28 EA

NDC:
00078-0708-02
UPC:
300780-708029PIQRAY 300MG TAB 56 By Novartis  Generic Name:
ALPELISIB

Description:
PIQRAY, 300MG, TABLETS, 2X28 EA

NDC:
00078-0708-02
UPC:
300780-708029Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.comVisit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.PIQRAY 250MG TAB 28 By Novartis NDC Code(s): 0078-0701-51, 0078-0701-84, 0078-0708-02, 0078-0708-51, view more
Packager: Novartis Pharmaceuticals Corporation
Category: HUMAN PRESCRIPTION DRUG LABEL

Rx Item-Piqray 250mg Tab 28 By Novartis

$20996.62$19996.78

Item No.: Rx00078-0715-02 NDC No.00078-0715-02 00078-715-02 00078071502 0007871502 UPC No.:300780-715027 3-00780-71502-7 300780715027 MPN 502 Only Lic.-Physician, Pharmacy, Dentist, Drug Mfg, Dist., Gov, Hospital, Lic.Lab, Naturalist, Naturopath, Np, Optometrist, Pharmacist, Pa, Physical Therapist, Podiatrist, Researchco., Uni., Va, Vet & Wholesalers In Scope Of Practice Can Order This Rx Item. 00078-0708-02 Rx Item-Piqray 250mg Tab 28 By Novartis

Have a question?

  Out of stock, please email us with the item number or product link at [email protected] for the quantity available, current pricing and eligibility to purchase.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use PIQRAY safely and effectively. See full prescribing information for PIQRAY.

PIQRAYïż½ (alpelisib) tablets, for oral use
Initial U.S. Approval: 2019
INDICATIONS AND USAGE
PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. (1)

DOSAGE AND ADMINISTRATION
Recommended dose: 300 mg (two 150 mg tablets) taken orally once daily with food. (2.2)
For adverse reactions, consider dose interruption, dose reduction, or discontinuation. (2.3)
DOSAGE FORMS AND STRENGTHS
Tablets: 50 mg, 150 mg, 200 mg (3)

CONTRAINDICATIONS
Severe hypersensitivity to PIQRAY or to any of its components (4).

WARNINGS AND PRECAUTIONS
Severe Hypersensitivity: Permanently discontinue PIQRAY. Promptly initiate appropriate treatment. (5.1)
Severe Cutaneous Reactions: Cases of severe cutaneous reactions, including Stevens-Johnson syndrome (SJS) and Erythema Multiforme (EM) were reported. Do not initiate treatment in patients with a history of SJS, EM, or Toxic Epidermal Necrolysis (TEN). Interrupt PIQRAY if signs or symptoms of severe cutaneous reactions are present, until etiology of the reaction has been determined. Consider consultation with a dermatologist. Permanently discontinue PIQRAY if SJS, EM, or TEN is confirmed. (5.2)
Hyperglycemia: Severe hyperglycemia, including ketoacidosis, was reported. The safety of PIQRAY in patients with Type 1 or uncontrolled Type 2 diabetes has not been established. Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment, monitor periodically. Initiate or optimize anti-hyperglycemic medications as clinically indicated. Interrupt, reduce dose, or discontinue PIQRAY if severe hyperglycemia occurs. (2.3, 5.3)
Pneumonitis: Severe cases of pneumonitis and interstitial lung disease have been reported. Monitor for clinical symptoms or radiological changes. Interrupt or discontinue PIQRAY if severe pneumonitis occurs. (2.3, 5.4)
Diarrhea: Severe cases of diarrhea, including dehydration and acute kidney injury, have been reported. Most patients experience diarrhea (Grade ≤ 2) during treatment with PIQRAY. Advise patients to start antidiarrheal treatment, increase oral fluids, and notify their healthcare provider if diarrhea occurs. Interrupt, reduce dose, or discontinue PIQRAY if severe diarrhea occurs. (2.3, 5.5)
Embryo-Fetal Toxicity: PIQRAY can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception (5.6, 8.1, 8.3). Also, refer to the Full Prescribing Information of fulvestrant for pregnancy and contraception information.
ADVERSE REACTIONS
Most common adverse reactions including laboratory abnormalities (all grades, incidence ≥ 20%) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, GGT increased, nausea, ALT increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, aPTT prolonged, and alopecia (6.1).


To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or WWW.FDA.GOV/MEDWATCH.

DRUG INTERACTIONS
CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. (7.1)
BCRP Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7.1)
CYP2C9 Substrates: Closely monitor when PIQRAY is coadministered with CYP2C9 substrates where decreases in the plasma concentration of these drugs may reduce activity. (7.2)
USE IN SPECIFIC POPULATIONS
Lactation: Advise not to breastfeed. (8.2)


See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 5/2019

PIQRAY 250MG TAB 28 By Novartis NDC Code(s): 0078-0701-51, 0078-0701-84, 0078-0708-02, 0078-0708-51, view more
Packager: Novartis Pharmaceuticals Corporation
Category: HUMAN PRESCRIPTION DRUG LABEL
PIQRAY 250MG TAB 28 By Novarti
PIQRAY 250MG TAB 28 By Novartis NDC Code(s): 0078-0701-51, 0078-0701-84, 0078-0708-02, 0078-0708-51, view more Packager: Novartis Pharmaceuticals Corporation Category: HUMAN PRESCRIPTION DRUG LABEL

PIQRAY 300MG TAB 56 By Novartis  Generic Name:
ALPELISIB

Description:
PIQRAY, 300MG, TABLETS, 2X28 EA

NDC:
00078-0708-02
UPC:
300780-708029
PIQRAY 300MG TAB 56 By Novarti
PIQRAY 300MG TAB 56 By Novartis Generic Name: ALPELISIB Description: PIQRAY, 300MG, TABLETS, 2X28 EA NDC: 00078-0708-02 UPC: 300780-708029

PIQRAY 300MG TAB 56 By Novartis  Generic Name:
ALPELISIB

Description:
PIQRAY, 300MG, TABLETS, 2X28 EA

NDC:
00078-0708-02
UPC:
300780-708029
PIQRAY 300MG TAB 56 By Novarti
PIQRAY 300MG TAB 56 By Novartis Generic Name: ALPELISIB Description: PIQRAY, 300MG, TABLETS, 2X28 EA NDC: 00078-0708-02 UPC: 300780-708029

PIQRAY 300MG TAB 56 By Novartis  Generic Name:
ALPELISIB

Description:
PIQRAY, 300MG, TABLETS, 2X28 EA

NDC:
00078-0708-02
UPC:
300780-708029
PIQRAY 300MG TAB 56 By Novarti
PIQRAY 300MG TAB 56 By Novartis Generic Name: ALPELISIB Description: PIQRAY, 300MG, TABLETS, 2X28 EA NDC: 00078-0708-02 UPC: 300780-708029

Want to do Research on this Med or need a large quantity? Email Details with quantity required to:sales@AmericanPharmaWholesale.com
Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.
AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.

PIQRAY 250MG TAB 28 By Novartis NDC Code(s): 0078-0701-51, 0078-0701-84, 0078-0708-02, 0078-0708-51, view more
Packager: Novartis Pharmaceuticals Corporation
Category: HUMAN PRESCRIPTION DRUG LABEL
PIQRAY 250MG TAB 28 By Novarti
PIQRAY 250MG TAB 28 By Novartis NDC Code(s): 0078-0701-51, 0078-0701-84, 0078-0708-02, 0078-0708-51, view more Packager: Novartis Pharmaceuticals Corporation Category: HUMAN PRESCRIPTION DRUG LABEL